IL326327A - טיפול בסרטן הערמונית - Google Patents
טיפול בסרטן הערמוניתInfo
- Publication number
- IL326327A IL326327A IL326327A IL32632726A IL326327A IL 326327 A IL326327 A IL 326327A IL 326327 A IL326327 A IL 326327A IL 32632726 A IL32632726 A IL 32632726A IL 326327 A IL326327 A IL 326327A
- Authority
- IL
- Israel
- Prior art keywords
- treatment
- prostate cancer
- prostate
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363517672P | 2023-08-04 | 2023-08-04 | |
| US202363603336P | 2023-11-28 | 2023-11-28 | |
| US202463617895P | 2024-01-05 | 2024-01-05 | |
| US202463670485P | 2024-07-12 | 2024-07-12 | |
| PCT/US2024/040691 WO2025034543A1 (en) | 2023-08-04 | 2024-08-02 | Treatment of prostate cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL326327A true IL326327A (he) | 2026-04-01 |
Family
ID=94535189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL326327A IL326327A (he) | 2023-08-04 | 2024-08-02 | טיפול בסרטן הערמונית |
Country Status (5)
| Country | Link |
|---|---|
| CN (1) | CN121925261A (he) |
| AU (1) | AU2024323161A1 (he) |
| IL (1) | IL326327A (he) |
| MX (1) | MX2026001352A (he) |
| WO (1) | WO2025034543A1 (he) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3746446T3 (da) * | 2018-01-31 | 2022-06-27 | Mirati Therapeutics Inc | PRC2-inhibitorer |
| US12252493B2 (en) * | 2019-06-05 | 2025-03-18 | Mirati Therapeutics, Inc. | Imidazo[1,2-c]pyrimidine derivatives as PRC2 inhibitors for treating cancer |
| EP4630004A1 (en) * | 2022-12-05 | 2025-10-15 | Oric Pharmaceuticals, Inc. | Treatment of prostate cancer having androgen receptor variants |
-
2024
- 2024-08-02 IL IL326327A patent/IL326327A/he unknown
- 2024-08-02 CN CN202480062624.8A patent/CN121925261A/zh active Pending
- 2024-08-02 AU AU2024323161A patent/AU2024323161A1/en active Pending
- 2024-08-02 WO PCT/US2024/040691 patent/WO2025034543A1/en active Pending
-
2026
- 2026-02-03 MX MX2026001352A patent/MX2026001352A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2025034543A1 (en) | 2025-02-13 |
| CN121925261A (zh) | 2026-04-24 |
| MX2026001352A (es) | 2026-03-02 |
| AU2024323161A1 (en) | 2026-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL320743A (he) | שיטה לטיפול בסרטן הערמונית | |
| GB202116903D0 (en) | Lasofoxifene treatment of aromatase-resistant er+ cancer | |
| IL307381A (he) | שיטות אבחון של סרטן הערמונית | |
| GB202107994D0 (en) | Treatment of cancer | |
| IL314687A (he) | טיפול בסרטן | |
| IL326327A (he) | טיפול בסרטן הערמונית | |
| IL312155A (he) | שיטה לטיפול בסרטן | |
| IL314798A (he) | שיטות לטיפול בסרטן הערמונית | |
| CA3300083A1 (en) | Treatment of prostate cancer | |
| GB202311976D0 (en) | Treatment of cancer | |
| GB202218181D0 (en) | Treatment of cancer | |
| GB202201803D0 (en) | Treatment of Cancer | |
| IL315569A (he) | שיטות לטיפול בסרטן | |
| GB202018062D0 (en) | Treatment of cancer | |
| GB202008037D0 (en) | Treatment of cancer | |
| HK40122526A (en) | Methods of treating prostate cancer | |
| IL325454A (he) | שיטת טיפול בסרטן הערמונית | |
| HK40087831A (en) | Methods of treating prostate cancer | |
| IL312332A (he) | שיטות לטיפול בסרטן | |
| IL325782A (he) | שיטות להתאמה אישית של טיפול בסרטן | |
| GB202507447D0 (en) | Treatment of cancer | |
| GB202505194D0 (en) | Treatment of cancer | |
| GB202416582D0 (en) | Treatment of cancer | |
| GB202415608D0 (en) | Treatment of cancer | |
| GB202406860D0 (en) | Treatment of cancer |